CART123 + Ruxolitinib in Relapsed/Refractory AML

NCT06768476 | Active Not Recruiting Phase 1 DMC FDA Drug

• 1 other identifier: 50424
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

Phase I, open-label study to assess the safety, feasibility, pharmacokinetics, and preliminary efficacy of CART123 cells given in combination with ruxolitinib in patients with relapsed or refractory acute myeloid leukemia (AML). All subjects will receive a single infusion of CART123 cells following ruxolitinib administration and lymphodepletion. Ruxolitinib dosing will begin at initiation of lymphodepleting chemotherapy (Day -6 ±1d) and continue for up to 14 days post CART123 administration.

Conditions

Relapsed AML; Refractory AML

Keywords

CART; refractory; relapsed; acute; myeloid; leukemia; AML

Outcome Measures

Primary Outcomes (3)

• Evaluate the safety of CART123 cells when given in combination with ruxolitinib

  Type, frequency, severity, and attribution of AEs/SAEs, including the incidence and severity of IEC-associated adverse events.

  15 Years

• Evaluate the safety of CART123 cells when given in combination with ruxolitinib

  Occurrence of treatment-limiting toxicities (TLTs)

  3 months

• Evaluate the safety of CART123 cells when given in combination with ruxolitinib

  The proportion of subjects requiring ruxolitinib dose modifications by assigned dose.

  3 months

Secondary Outcomes (8)

• Evaluate study feasibility

  3 months

• Evaluate study feasibility

  3 months

• Describe preliminary efficacy of CART123 cells given in combination with ruxolitinib

  From enrollment to Day 28, post treatment.

• Describe preliminary efficacy of CART123 cells given in combination with ruxolitinib

  15 years

• Describe preliminary efficacy of CART123 cells given in combination with ruxolitinib

  15 Years

Study Arms (3)

Arm A: DL1

EXPERIMENTAL

* LD Chemo: Day -6 to Day -4 (±1d) * Ruxolitinib: Daily beginning on Day -6 (±1d) through D14 post CART123 infusion. * CART123 Cells: Single infusion on Day 0

Biological: CART123 Cells; Drug: Ruxolitinib 10 MG

Arm A: DL-1

EXPERIMENTAL

* LD Chemo: Day -6 to Day -4 (±1d) * Ruxolitinib: Daily beginning on Day -6 (±1d) through D14 post CART123 infusion. * CART123 Cells: Single infusion on Day 0

Biological: CART123 Cells; Drug: Ruxolitinib 5 MG

Arm B: DL-1

EXPERIMENTAL

* LD Chemo: Day -6 (-1d) to Day -2 (-1d) * Venetoclax: Day -6 (-1d) through Day +7 - Day +14 post-CART123 infusion * Ruxolitinib: Daily beginning on Day -1 through Day +7 post CART123 infusion. * CART123 Cells: Single infusion on Day 0

Biological: CART123 Cells; Drug: Ruxolitinib 5 MG

Interventions

CART123 Cells BIOLOGICAL

1.3x10\^8 CART123 cells

Arm A: DL-1; Arm A: DL1; Arm B: DL-1

Ruxolitinib 10 MG DRUG

Twice Daily

Arm A: DL1

Ruxolitinib 5 MG DRUG

Twice Daily

Arm A: DL-1; Arm B: DL-1

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \. Signed informed consent form 2. Male or female age ≥ 18 years. 3. Patients with active acute myeloid leukemia (AML) with no available curative treatment options using currently available therapies. This is specifically defined as one of the following:
• AML that has not achieved a complete remission or morphologic leukemia free state by ELN 2022 criteria57 after at least 2 cycles of induction (includes partial remission or refractory/primary refractory disease), OR:
• AML relapsed following allogeneic stem cell transplantation (including MDS evolved to AML post-allogeneic stem cell transplant).
• i. Note: Morphologic relapse is not required; Patient may have persistent/recurrent disease-associated molecular, phenotypic or cytogenetic abnormalities (i.e., MRD) at any time after allogeneic HCT to qualify. Mutations involving DNMT3A, ASXL1 or TET2 should not count as molecular MRD+ disease unless accompanied by other, more specific disease-related molecular or cytogenetic abnormalities.
• \. Patients with relapsed disease after prior allogeneic SCT must be at least 3 months from transplantation (where receipt of the stem cell product is defined as day 0) and must not require systemic immunosuppression (for prevention or treatment of GVHD).
• \. Patients must have a suitable stem cell donor identified with projected ability to proceed to transplant within 6-8 weeks of CART123 infusion if clinically indicated. Donor may be matched or mismatched and must be found to be suitable according to the institution's standard criteria.
• \. Adequate organ function defined as:
• Estimated creatinine clearance \> 35mL/min using the CKD-EPI equation for Glomerular Filtration Rate (GFR); Patients must not be on dialysis
• ALT/AST ≤ 5x upper limit of normal range
• Direct bilirubin ≤ 2.0 mg/dl, unless the subject has Gilbert's syndrome (≤3.0 mg/dl)
• Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygen \> 92% on room air
• Left Ventricle Ejection Fraction (LVEF) ≥ 40% confirmed by transthoracic echocardiography or MUGA scan.
• \. ECOG Performance Status 0-2.

You may not qualify if:

• \. Patients with the JAK2 V617F mutation by PCR or next generation sequencing. 2. Patients with signs or symptoms indicative of active CNS involvement. A CNS evaluation should be performed as clinically appropriate to rule out CNS involvement.
• \. Patients with relapsed AML with t(15:17). 4. Active hepatitis B, active hepatitis C, or other active, uncontrolled infection.
• \. Active acute or chronic GVHD requiring systemic therapy. 6. Class III/IV cardiovascular disability according to the New York Heart Association Classification.
• \. Clinically apparent arrhythmia or arrhythmias that are not stable on medical management within two weeks of physician-investigator confirmation of eligibility.
• \. Dependence on systemic steroids or immunosuppressant medications. For additional details regarding use of steroid and immunosuppressant medications.
• \. Planned use of fluconazole within the anticipated study treatment window. For additional details on concomitant medication restrictions.
• \. Receipt of prior CART123 therapy. 11. Pregnant or nursing (lactating) patients. Participants of reproductive potential must agree to use acceptable birth control methods.
• \. Active autoimmune disease requiring systemic immunosuppressive treatment equivalent to ≥ 10mg of prednisone. Patients with autoimmune neurologic diseases (such as MS) will be excluded.
• \. History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40).

Sponsors & Collaborators

• University of Pennsylvania: lead
• Novartis: collaborator

Study Sites (1)

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location

MeSH Terms

Conditions

Leukemia, Myeloid, Acute; Recurrence; Leukemia

Interventions

ruxolitinib

Condition Hierarchy (Ancestors)

Leukemia, Myeloid; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Saar Gill, MD, PhD

  University of Pennsylvania

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 6, 2025
• First Posted: January 10, 2025
• Study Start: February 28, 2025
• Primary Completion (Estimated): March 1, 2045
• Study Completion (Estimated): March 1, 2045
• Last Updated: January 16, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)